Aromatase inhibitors in precocious puberty: Rationale and experience to date

Treatments in Endocrinology

Volumn 3, Issue 3, 2004, Pages 141-151

  Eugster, Erica A ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DESLORELIN; ESTROGEN; FADROZOLE; FLUDROCORTISONE; FLUTAMIDE; GONADORELIN DERIVATIVE; GONADOTROPIN; HYDROCORTISONE; LETROZOLE; SPIRONOLACTONE; TESTOLACTONE; TESTOSTERONE;

ABDOMINAL PAIN; ALBRIGHT SYNDROME; BONE MATURATION; CONGENITAL ADRENAL HYPERPLASIA; DIARRHEA; ESTROGEN ACTIVITY; FEMALE; FOOT DISEASE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAND DISEASE; HEADACHE; HUMAN; MALE; MUSCLE WEAKNESS; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SEXUAL DEVELOPMENT; SHORT STATURE; TUMOR;

AROMATASE INHIBITORS; BONE DENSITY; BONE DEVELOPMENT; ESTROGENS; HUMANS; PUBERTY, PRECOCIOUS;

EID: 2642558611     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403030-00002     Document Type: Review

References (95)

1. Quigley CA, Pescovitz OH. Premature thelarche and precocious puberty. Curr Ther Endocrinol Metab 1997; 6: 7-13
2. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999; 104 (4 Pt 1): 936-41
3. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings Network. Pediatrics 1997; 99 (4): 505-12
4. Kaplowitz PB, Slora EJ, Wasserman RC, et al. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics 2001; 108 (2): 347-53
5. Papadimitriou A, Gousia E, Pitaouli E, et al. Age at menarche in Greek girls. Ann Hum Biol 1999; 26 (2): 175-7
6. Lindgren G. Pubertal stages 1980 of Stockholm school children. Acta Paediatr 1996; 85 (11): 1365-7
7. Chumlea WC, Schubert CM, Roche AF, et al. Age at menarche and racial comparisons in US girls. Pediatrics 2003; 111 (1): 110-3
8. Sun SS, Schubert CM, Chumlea WC, et al. National estimates of the timing of sexual maturation and racial differences among US children. Pediatrics 2002; 110 (5): 911-9
9. Volta C, Bernasconi S, Cisternino M, et al. Isolated premature thelarche and thelarche variant: clinical and auxological follow-up of 119 girls. J Endocrinol Invest 1998; 21 (3): 180-3
10. Reiter EO, Lee PA. Delayed puberty. Adolesc Med 2002; 13 (1): 101-18
11. Salardi S, Cacciari E, Mainetti B, et al. Outcome of premature thelarche: relation to puberty and final height. Arch Dis Child 1998; 79 (2): 173-4
12. Ghizzoni L, Milani S. The natural history of premature adrenarche. J Pediatr Endocrinol Metab 2000; 13 Suppl. 5: 1247-51
13. Kaplan SL, Grumbach MM. Clinical review 14: pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 1990; 71 (4): 785-9
14. Bridges NA, Christopher JA, Hindmarsh PC, et al. Sexual precocity: sex incidence and aetiology. Arch Dis Child 1994; 70 (2): 116-8
15. Dacou-Voutetakis C. Female sexual precocity. Ann N Y Acad Sci 1997; 816: 209-18
16. Merke DP, Cutler Jr GB. Evaluation and management of precocious puberty. Arch Dis Child 1996; 75 (4): 269-71
17. De Sanctis V, Corrias A, Rizzo V, et al. Etiology of central precocious puberty in males: the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000; 13 Suppl. 1: 687-93
18. Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr 1986; 108 (1): 47-54
19. Eckert KL, Wilson DM, Bachrach LK, et al. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics 1996; 97 (4): 517-9
20. Neely EK, Wilson DM, Lee PA, et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995; 127 (1): 47-52
21. Crowley Jr WF, Comite F, Vale W, et al. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981; 52 (2): 370-2
22. Mul D, Bertelloni S, Carel JC, et al. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 2002; 58 (1): 1-7
23. Carel JC, Ecosse E, Nicolino M, et al. Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. BMJ 2002; 325 (7355): 70
24. Klein KO, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86 (10): 4711-6
25. Bertelloni S, Baroncelli GI, Ferdeghini M, et al. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr 2000; 159 (5): 369-74
26. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function [published erratum appears in J Clin Endocrinol Metab 2000 Feb; 85 (2): 657]. J Clin Endocrinol Metab 1999; 84 (12): 4583-90
27. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function [published erratum appears in J Clin Endocrinol Metab 2000 Feb; 85 (2): 657]. J Clin Endocrinol Metab 1999; 84 (12): 4583-90
28. Miller WL. Clinical review 54: genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab 1994; 78 (2): 241-6
29. Cutler Jr GB, Laue L. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1990; 323 (26): 1806-13
30. Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30 (1): 15-30
31. Lim YJ, Batch JA, Warne GL. Adrenal 21-hydroxylase deficiency in childhood: 25 years' experience. J Paediatr Child Health 1995; 31 (3): 222-7
32. Moran C, Azziz R, Carmina E, et al. 21-hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 2000; 183 (6): 1468-74
33. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349 (8): 776-88
34. Van Wyk JJ, Ritzen EM. The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88 (7): 2993-8
35. Chowdhuri S, Dharmalingam M, Kumar KM. Adrenal tumor presenting as precocious puberty. Indian J Pediatr 2001; 68 (4): 351-2
36. Phornphutkul C, Okubo T, Wu K, et al. Aromatase P450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty. J Clin Endocrinol Metab 2001; 86 (2): 649-52
37. Schulin-Zeuthen C, Yamamoto M, Pires Y, et al. Peripheral precocious puberty caused by a juvenile granulosa cell ovarian tumor, with iso and heterosexual manifestations in a six year old girl [Spanish]. Rev Med Chil 2003; 131 (1): 71-6
38. Iliev DI, Ranke MB, Wollmann HA. Mixed gonadal dysgenesis and precocious puberty. Horm Res 2002; 58 (1): 30-3
39. Englund AT, Geffner ME, Nagel RA, et al. Pediatric germ cell and human chorionic gonadotropin-producing tumors: clinical and laboratory features. Am J Dis Child 1991; 145 (11): 1294-7
40. Starzyk J, Starzyk B, Bartnik-Mikuta A, et al. Gonadotropin releasing hormone-independent precocious puberty in a 5-year-old girl with suprasellar germ cell tumor secreting β-HCG and α-fetoprotein. J Pediatr Endocrinol Metab 2001; 14 (6): 789-96
41. Zimmerman PA, Francis GL, Poth M. Hormone-containing cosmetics may cause signs of early sexual development. Mil Med 1995; 160 (12): 628-30
42. No authors listed. Estrogens in cosmetics. Med Lett Drugs Ther 1985; 27 (690): 54-5
43. Ramos AS, Bower BF. Pseudoisosexual precocity due to cosmetic ingestion. JAMA 1969; 207 (2): 368-9
44. Saenz de Rodriguez CA, Bongiovanni AM, Conde de Borrego L. An epidemic of precocious development in Puerto Rican children. J Pediatr 1985; 107 (3): 393-6
45. DiMeglio LA, Pescovitz OH. Disorders of puberty: inactivating and activating molecular mutations. J Pediatr 1997; 131 (1 Pt 2): S8-12
46. Shenker A, Laue L, Kosugi S, et al. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365 (6447): 652-4
47. Shenker A. Activating mutations of the lutropin choriogonadotropin receptor in precocious puberty. Receptors Channels 2002; 8 (1): 3-18
48. Themmen AP, Verhoef-Post M. LH receptor defects. Semin Reprod Med 2002; 20 (3): 199-204
49. Latronico AC, Shinozaki H, Guerra Jr G, et al. Gonadotropin-independent precocious puberty due to luteinizing hormone receptor mutations in Brazilian boys: a novel constitutively activating mutation in the first transmembrane helix. J Clin Endocrinol Metab 2000; 85 (12): 4799-805
50. Gromoll J, Partsch CJ, Simoni M, et al. A mutation in the first transmembrane domain of the lutropin receptor causes male precocious puberty. J Clin Endocrinol Metab 1998; 83 (2): 476-80
51. Muller J, Gondos B, Kosugi S, et al. Severe testotoxicosis phenotype associated with Asp578->Tyr mutation of the lutrophin/choriogonadotrophin receptor gene. J Med Genet 1998; 35 (4): 340-1
52. Shenker A. G protein-coupled receptor structure and function: the impact of disease-causing mutations. Baillieres Clin Endocrinol Metab 1995; 9 (3): 427-51
53. Babovic-Vuksanovic D, Donaldson MD, Gibson NA, et al. Hazards of ketoconazole therapy in testotoxicosis. Acta Paediatr 1994; 83 (9): 994-7
54. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325 (24): 1688-95
55. Levine MA. Clinical implications of genetic defects in G proteins: oncogenic mutations in G alphas as the molecular basis for the McCune-Albright syndrome. Arch Med Res 1999; 30 (6): 522-31
56. Foster CM, Feuillan P, Padmanabhan V, et al. Ovarian function in girls with McCune-Albright syndrome. Pediatr Res 1986; 20 (9): 859-63
57. Shenker A, Weinstein LS, Sweet DE, et al. An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 1994; 79 (3): 750-5
58. Feuillan PP, Shawker T, Rose SR, et al. Thyroid abnormalities in the McCune-Albright syndrome: ultrasonography and hormonal studies. J Clin Endocrinol Metab 1990; 71 (6): 1596-601
59. Akintoye SO, Chebli C, Booher S, et al. Characterization of Gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002; 87 (11): 5104-12
60. Kirk JM, Brain CE, Carson DJ, et al. Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 1999; 134 (6): 789-92
61. Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993; 123 (4): 509-18
62. Syed FA, Chalew SA. Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: a preliminary report. J Pediatr Endocrinol Metab 1999; 12 (1): 81-3
63. Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003; 143 (1): 60-6
64. Mauras N. Growth hormone and sex steroids: interactions in puberty [published erratum appears in Endocrinol Metab Clin North Am 2001 Dec; 30 (4): 319]. Endocrinol Metab Clin North Am 2001; 30 (3): 529-44
65. Mauras N. Growth hormone and sex steroids: interactions in puberty [published erratum appears in Endocrinol Metab Clin North Am 2001 Dec; 30 (4): 319]. Endocrinol Metab Clin North Am 2001; 30 (3): 529-44
66. Veldhuis JD, Metzger DL, Martha Jr PM, et al. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement. J Clin Endocrinol Metab 1997; 82 (10): 3414-20
67. Mauras N, Hayes V, O'Brien KO. Estrogen treatment and estrogen suppression: metabolic effects in adolescence. J Pediatr Endocrinol Metab 2000; 13 Suppl. 6: 1431-7
68. Eugster EA, Pescovitz OH. Advances in the treatment of precocious puberty. Expert Opin Investig Drugs 2001; 10 (9): 1623-30
69. Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999; 84 (12): 4677-94
70. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man [published erratum appears in N Engl J Med 1995 Jan 12; 332 (2): 131]. N Engl J Med 1994; 331 (16): 1056-61
71. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man [published erratum appears in N Engl J Med 1995 Jan 12; 332 (2): 131]. N Engl J Med 1994; 331 (16): 1056-61
72. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in mate and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80 (12): 3689-98
73. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337 (2): 91-5
74. Bilezikian JP, Morishima A, Bell J, et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339 (9): 599-603
75. van der Eerden BC, Karperien M, Wit JM. The estrogen receptor in the growth plate: implications for pubertal growth. J Pediatr Endocrinol Metab 2001; 14 Suppl. 6: 1527-33
76. Lonning PE. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs Aging 2002; 19 (4): 277-98
77. Lonning PE. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clin Pharmacokinet 2003; 42 (7): 619-31
78. Feuillan P, Merke D, Leschek EW, et al. Use of aromatase inhibitors in precocious puberty. Endocr Relat Cancer 1999; 6 (2): 303-6
79. Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989; 320 (8): 496-502
80. Laue L, Jones J, Barnes KM, et al. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab 1993; 76 (1): 151-5
81. Leschek EW, Jones J, Barnes KM, et al. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84 (1): 175-8
82. Foster CM, Pescovitz OH, Comite F, et al. Testolactone treatment of precocious puberty in McCune-Albright syndrome. Acta Endocrinol (Copenh) 1985; 109 (2): 254-7
83. Feuillan PP, Foster CM, Pescovitz OH, et al. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986; 315 (18): 1115-9
84. Feuillan PP, Jones J, Cutler Jr GB. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993; 77 (3): 647-51
85. Nunez SB, Calis K, Cutler GB, et al. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 2003; 88: 5730-3
86. Roth C, Freiberg C, Zappel H, et al. Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002; 15 Suppl. 3: 945-8
87. Kunz GJ, Mao CS, Gottschalk ME. Anastrozole use during precocious puberty in McCune-Albright syndrome [abstract no. P1-673]. The Endocrine Society's 85th annual meeting; 2003 Jun 19-20; Philadelphia. Philadelphia (PA): The Endocrine Society Press, 2003: 293
88. Feuillan P, Karim C, Suvimol H, et al. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome [abstract no. 778]. Proceedings of the Pediatric Academic Societies annual meeting; 2003 May 3-6; Seattle. Pediatric Research Suppl 2003; 53(4): 136A
89. Van Wyk JJ, Gunther DF, Ritzen EM, et al. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996; 81 (9): 3180-90
90. Laue L, Merke DP, Jones JV, et al. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996; 81 (10): 3535-9
91. Merke DP, Keil MF, Jones JV, et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85 (3): 1114-20
92. Mauras N, Hayes VY, Vieira NE, et al. Profound hypogonadism has significant negative effects on calcium balance in males: a calcium kinetic study. J Bone Miner Res 1999; 14 (4): 577-82
93. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83 (6): 1886-92
94. Wickman S, Sipila I, Ankarberg-Lindgren C, et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357 (9270): 1743-8
95. Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the P450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003; 88 (8): 3785-93